港股異動 | 中國飛鶴(06186.HK)一度升至10%破頂 市值超2200億港元
格隆匯1月19日丨中國飛鶴(06186.HK)午後一度拉昇至10%,月內股價已升超35%。報25.2港元再創新高價,暫成交9.2億港元,總市值超2200億港元。高盛料2021年保持強勁的發展勢頭,上調中國飛鶴目標價15%至24.7港元,重申買入評級。該行相信公司將在未來5年內在全球範圍內獲得80%的增量市場價值收益。美銀證券日前認為中國飛鶴擁有獨特優勢可受惠於行業結構性機遇,並通過增加市場份額以進一步鞏固其領先地位。首予中國飛鶴“買入”評級,目標價27港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.